Evidence map›Paper›PMID 36176448›Full record

ArticleFrontiers in pharmacology2022

A real-world cost-effectiveness analysis of nebulized budesonide and intravenous methylprednisolone in acute exacerbation of chronic obstructive pulmonary disease.

Yong-Li Gu, Zeng-Xian Sun, Ying Sun, Yan Wen, Xin Guan, Dao-Li Jiang, Cong Cheng, Huan Gu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yong-Li GuDepartment of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, China.
Zeng-Xian SunDepartment of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, China.
Ying SunDepartment of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, China.
Yan WenDepartment of Respiratory, The First People's Hospital of Lianyungang, Lianyungang, China.
Xin GuanSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Dao-Li JiangDepartment of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Cong ChengDepartment of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, China.
Huan GuDepartment of Pharmacy, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, China.
The First People’s Hospital of Lianyungang · CNChina Pharmaceutical University · CNNanjing University of Chinese Medicine · CNState Key Laboratory of Respiratory Disease · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute exacerbationbudesonidechronic obstructive pulmonary diseasecost-effectiveness analysismethylprednisoloneminimum cost analysis

Identifiers

PMID36176448
PMCPMC9514722
OpenAlexW4296007253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.